Pre-Concentration Approaches Combined with Capillary Electrophoresis in Bioanalysis of Chiral Cardiovascular Drugs

Samin Hamidi1, Abolghasem Jouyban2*

1Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
2Pharmacutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

ABSTRACT

Currently, there is a remarkable interest in the separation and quantification of enantiomeric compounds because of their importance in biochemistry, therapeutic drug monitoring (TDM), pharmaceutical, forensic, etc. In past decades the pharmacopoeia was governed by racemates, but nowadays the U.S. Food and Drug Administration (FDA) exclusively has been issued a statement that racemic new drugs could not be marketed unless they are thoroughly investigated of the pharmacological and toxicological properties of pure enantiomers. Demands for accurate and precise analytical method for separation and determination of drugs enantiomers and their metabolites in biological fluids are highlighted. Capillary zone electrophoresis (CZE) is an interesting technique that shows promise for the resolution of enantiomers. This is carried out by adding suitable chiral selector to the background electrolyte results to enantioseparation. According to WHO organization report, cardiovascular diseases (CVDs) rank the leading cause of death, globally. Therefore the related risk factors addressing CVDs should be considered and diagnose to prevent the disease. This article provides a brief review on applying off-line and on-line sample preconcentration methods for enhancing the detection limit of cardiovascular drugs.

Introduction
Chirality

Stereochirality is a field of chemistry involving the study of geometric arrangement of atoms in molecules. Chirality is described as the optical property of a rigid materials such as drugs. Chiral compounds have identical formula but they are distinguished in spatial arrangement which shows non-superimposable mirror images with each other (optical isomers).

Table 1. Definitions of important terms in stereochemistry.

| Term             | Definition                                                                 |
|------------------|---------------------------------------------------------------------------|
| Stereoisomers    | Stereoisomers have similar molecular formula but differ in spatial orientation of their atoms |
| Enantiomers      | Enantiomers are two stereoisomers with non-superimposable mirror images    |
| Distomer         | Enantiomer with lower biological activity                                  |
| Eutomer          | Enantiomer with higher biological activity                                 |
| Racemate         | A mixture of equal amounts of enantiomers                                  |
| Chiral switch    | A rasemate switch to single enantiomer                                     |
| Epimerization    | Bioinversion of enantiomers                                                |
| (+) Optical isomer | Rotates the light plane clockwise (dextrorotary)                           |
| (-) Optical isomer | Rotates the light plane counter-clockwise (levorotary)                    |
| (R) and (S)      | According to enantiomer configurations which are right- or left-handed     |

Chiral molecules can rotate plane of polarized light in opposite directions and according to their optical rotation of plane-polarized light, they can be classified as (+) and (-) enantiomers. On the basis of another classification, amino acids and sugars are distinguished as (d) and (l) system. For example one enantiomer rotates the light to the left direction (levorotary or (-)enantiomer or R-form), therefore the other will rotate

*Corresponding Author: Abolghasem Jouyban, Tel: (+98) 41 33379723, Fax: (+98) 41 33363231, E-mail: ajouyban@hotmail.com
©2015 The Authors. This is an open access article and applies the Creative Commons Attribution (CC BY-NC) license to the published article. Non-commercial uses of the work are permitted, provided the original work is properly cited.
the light to the right (dextrorotatory or (+)-enantiomer or S-form). It is concluded that each enantiomer may behave very distinguished in its biological effects. There are several examples that the prefixes have been used to mark active pharmaceutical ingredients (API) e.g. es- (esomeprazole), ar- (arabipivacaine), lev- (levibuprofen) and dex- (dexamethylphenidate). More defined terms related to stereochemistry are shown in Table 1.

**Chirality in biological system**

Basic building blocks in biological system such as amino acids, carbohydrates, and lipids show chirality. Furthermore, biological matrices or drug targets such as receptors, enzymes, proteins and membranes (e.g. phospholipids) display three-dimensional structure. Enantiomers of a chiral molecule show identical properties in an isotropic environment but in anisotropic environments they exert different properties. Biochemical interactions are stereoselective, therefore the drugs interactions with corresponding targets should be stereoselective. Easson and Stedman in 1993 suggested the “three point fit” model between the active enantiomer and its receptor. As is illustrated in Figure 1, the biological response of drugs depends on their binding behavior. Therefore, it is reasonable that a chiral drug molecule may show different therapeutic properties as its enantiomer counterpart has the different binding mode with biological targets.

*Figure 1. Interaction between chiral molecule and receptor.*

**Drugs with chiral center**

Drugs with chiral centers show a remarkable attention in the pharmaceutical field. About 70% of drugs in the pharmaceutical market are chiral compounds, and it is growing very fast. In better words, almost 1 in 4 of marketed drugs is in racemic form rather than their enantiomers. The fact that 9 of top 10 drugs have chiral active ingredients, may emphasize the important aspect of chiral drugs in pharmaceutical investigations. In general, administration of more active isomer of racemic drugs causes to following advantages: diminishing probable side effects due to the antipode (counterpart) isomer, decrease in producing of unwanted isomer, halved dosage for a patient and new commercial opportunities for racemic switching.

Drugs with chiral center can be categorized in three major groups:

1. Racemic drugs with one major bioactive enantiomer
2. Racemic drugs with equally bioactive enantiomers
3. Racemic drugs with chiral inversion

Most of the attention was focused on drugs with one enantiomer having major activity. Another enantiomer can be therapeutically present inactive, with toxic effects or even with reducing effect on active form. Enantiomers may differ in both their pharmacodynamic and pharmacokinetic profiles. Thalidomide is a famous example that elucidates the importance of chirality in human body. It was synthesized in 1953 as a racemat and prescribed for morning sickness in pregnant women. Unfortunately, it leads to born almost 10,000 babies with defects in Europe. Although the first estimation was indicated the undesirable role of (S)-enantiomer in teratogenicity, but subsequent researches proved that both enantiomers have equal teratogenic potency in the rabbit. Another hypothesis discussed on the bioinversion of thalidomide in acidic media. Although the chirality story about thalidomide is a disaster but the great impact of thalidomide in development of chiral drugs is not deniable. Despite the dark past of thalidomide, it is transformed gradually into a pretty useful drug. It is also noteworthy to mention that thalidomide currently has shown hopes to treat leprosy, acquired immunodeficiency syndrome (AIDS), behchet disorder, lupus, sjogren syndrome, rheumatoid arthritis, inflammatory bowel disease, molecular degeneration and some cancers. Recent studies confirm that (S)-thalidomide slows down the growth of tumors as well as angiogenesis thus it contributes in revolutionized treatment of myeloma. Contrary to the fact that thalidomide shows very toxic side effects such as peripheral neuropathy, somnolence, constipation, rash, deep vein thrombosis and teratogenicity, but the statistics show that till 2001 it has survived the hundreds of years of life in myeloma treatment.

**Importance of enantioseparation**

There is a high demand for enantioseparation at analytical scale for therapeutic drug monitoring (TDM), optimization of pharmacotherapy and for research in pharmacokinetic and pharmacodynamic investigations. Furthermore, as certain enantiomers represent illicit or banned substances, chiral discrimination shows an important challenge in forensic analysis and doping control in biological fluids (typically plasma, serum or urine). Nowadays, TDM is widely accepted as an applied method to improve the effectiveness and safety of therapeutic agents. TDM is based on measurement of
drug concentrations in biological fluids to assess useful information to personalized dosage, keep concentrations within a target range, increase efficacy or decrease toxicity of drugs. Because of above mentioned rationals, since 1992 the Food and Drug Administration (FDA) and the European Committee for Proprietary Medicinal Products (CPMP) have been made a statement in order to investigate the enantiomers of chiral drugs with respect to their individual properties before taken to market as a racemic form or a pure enantiomer. Inactive enantiomers are going to be administrated less, but they provide information to design safe generation of useful analogues.

**Electromigration techniques in chiral separation**

There are various enantioseparation methods such as high-performance liquid chromatography (HPLC), gas chromatography (GC), supercritical-fluid chromatography (SFC), and capillary electrophoresis (CE). Stereospecific drugs resolution with liquid chromatography (LC) methods are accompanied with rather expensive stationary phases and consumption a large amount of organic solvents. In the last 20 years, chiral separation techniques based on capillary electromigration methods have been intensively studied. CE has been accepted as a powerful separation tool in chiral and achiral compounds. The use of CE to discriminate between enantiomers dated back to the work of Gassmann et al. in 1985. One of the important features of CE is its versatility in the kinds of separation modes allowing the separation of a wide range of analytes from macromolecules to small ions for many different applications such as food, pharmaceuticals, chiral, etc. Capillary zone electrophoresis (CZE) is the simplest version of CE and modification on this basic form creates other modes such as micellar electrokinetic chromatography (MEKC), capillary gel electrophoresis (CGE), capillary isoelectric focusing (CIEF), capillary isochromatography (CITP), non aqueous capillary electrophoresis (NACE) and capillary electrochromatography (CEC).

CE has been proven as a powerful instrument in the chiral analysis area due to its low samples and solvents consumption, high separation efficiency, rapid method development, fast migration times, versatility, possibility of adding various selectors to the back ground electrolyte (BGE), and simple instrumentation. Chiral separation by CE is performed either indirectly by construction a diastereomeric pair with chiral compound that can be resolved under achiral condition or directly which separation is performed with addition of the chiral selector/selectors into BGE. The frequently used CE modes in enantioseparation include; CZE, MEKC, NACE and CEC. Gübitz and Schmid documented the recent progresses in chiral separation by various modes of CE. MEKC is performed by solubilization of pseudostationary phase such as surfactants into BGE. CEC is a hybrid form of chromatographic and electrophoretic principles, extends the utilization of chromatographic principles to CE-based enantioseparation. Selectors can be both bond on stationary phase or added into BGE. It can be useful for aqueous or non-aqueous buffers and those selectors with UV absorption or risk of mass-spectrometer (MS) detector contamination.

Among variety of CE modes, most of them utilize aqueous BGEs and this creates a constraint for the use of partially soluble selectors, therefore NACE is providing for this purpose. Additionally, non-aqueous solvents show good compatibility with MS detection. Also, NACE is beneficial for those sample preparation methods that analytes extract into apolar and viscose solvent. So, the need for solvent evaporation, back-extraction and/or sample reconstruction is eliminated and sample injection can be directly applied.

**Capillary zone electrophoresis (CZE): Basic principle**

The following section will be dedicated to CZE, as the most commonly used version of CE and also this mode is relevance in the present project. CZE is the most widely used mode of CE, developed since the late 1980s, which the mechanism is based on analytes differences in charge to size ratios and therefore differences in electrophoretic mobilities.

In CZE, the separation is performed by differential migration of analytes upon the application of a current through the capillary. Figure 2 shows the schematic view of a typical CE instrument. The apparatus consist of a fused silica capillary (usually around 25 to 100 μm internal diameter (i.d.) while both ends were immersed in buffer solutions (also known as a (BGE)). Electrodes are connected to both end of the capillary with a high voltage power supply. In a regular analysis, the sample is loaded into column at the anodic (positive) end and then with applying the voltage, analytes migrate towards the cathodic (negative) end, where the detector is located. The applied voltage also causes to make a difference across the capillary and results a migration of a bulk portion of liquid called electro-osmotic flow (EOF).

**Mechanism of enantioseparation by CZE**

In direct separation mode in CZE, chiral resolution is performed by adding chiral selector into BGE. Among the various chiral selectors, i.e. chiral micelles, crown ethers, chiral ligands, proteins, oligo- and polysaccharides, and macrocyclic antibiotics, cyclodextrins

---

**Figure 2.** Schematic of a capillary electrophoresis unit.

**Pharmaceutical Sciences, December 2015, 21, 229-243 | 231**
(CDs) and CD derivatives exhibit acceptable results in chiral resolution for a wide range of analytes. More details about the mechanism can be found in references.\textsuperscript{29,30} CDs are cyclic oligosaccharides that become the most popular selectors in chiral separation due to their availability, UV-transparent, presence in charged and neutral forms and almost low cost. Commercial CDs are α-CD, β-CD and γ-CD which differ in the number of glucose units (i.e., α-CD contains 6 glucose units, β-CD has 7 glucose units (Figure 3) and γ-CD has 8 glucose units).

\begin{figure}
\centering
\includegraphics[width=\textwidth]{beta_CDstructure.png}
\caption{Chemical structure of β-CD.}
\end{figure}

Descriptions the theoretical background on how the separation occurred, present in equations 1 and 2 The thermodynamic complexation equilibria between the enantiomers R and S and the CD are defined by the complexation constants $K_R$ and $K_S$, respectively, assuming the formation of a 1:1 complex between the enantiomers and the chiral selector.

\begin{equation}
R + \text{CD} \rightleftharpoons R\text{CD} \quad K_R = \frac{[R\text{CD}]}{[R][\text{CD}]} \quad \text{Eq. (1)}
\end{equation}

\begin{equation}
S + \text{CD} \rightleftharpoons S\text{CD} \quad K_S = \frac{[S\text{CD}]}{[S][\text{CD}]} \quad \text{Eq. (2)}
\end{equation}

Effective mobility $\mu_{\text{eff}}^R$ of an analyte is the sum of its portion traveling in the free form, $\mu_R$, and the complexed form, $\mu_{\text{eff}}^R$. The differential $\mu_{\text{eff}}$ between enantiomers indicates the separation and the fundamental equation developed by Wren and Rowe in equation 3.\textsuperscript{31}

\begin{equation}
\Delta\mu = \mu_{\text{eff}}^R - \mu_{\text{eff}}^S = \frac{\mu_R + \mu_{\text{eff}}^R}{1 + K_R} - \frac{\mu_S + \mu_{\text{eff}}^S}{1 + K_S} \quad \text{Eq. (3)}
\end{equation}

$\mu_{\text{eff}}^R$ and $\mu_{\text{eff}}^S$ are the effective mobilities of the R- and S-enantiomers, $\mu_R$ and $\mu_S$ are the mobilities of the complexed R- and S-enantiomers and [C] is the concentration of the CD.

Two main points can be driven from equation 3. Differences in enantiomers complexation constants cause to enantioseparation. Another important concluded tip from the equation 3 is that the chiral selector concentration plays a crucial role in enantioseparations and should be in optimum value. In order to have chiral discrimination, enantiomers must show differing chromatographic interactions with the chiral selector whereas they have virtually identical electrophoretic mobilities in achiral media. The enantiomers are inserted into CDs hydrophobic cavity and based on their different interactions they can be resolved. Now these complexes differ in electrophoretic mobibly due to their charge-to-size differences and thus resolved. Beside this inclusion phenomenon, the interaction between selector and selectant may included molecular interactions including; ion-ion bonds, dipole-dipole bonds such as hydrogen bonds, van der Waals forces and ion-dipole bonds. CDs are inherently chiral compounds, therefore, binding of enantiomers results in diastereomeric complexes. Several disadvantages are associated with indirect enantioseparaiton methods including; a) need of a functional group that can be formed a diastereomeric pair b) derivatization reagent should be in high level of purity and c) forming diastereomeric pair add time-consuming process to analyzing steps. The improvement in chiral separation is mostly associated with direct separation methods which are based on the interaction between a chiral selector and optical stereoisomer.

Detection in CE

The most commonly used detection system in CE is a UV absorbance detector, with detection at single wavelength, multiple wavelengths or even over a wide range of wavelengths using a photo diod array detector. There is a limitation in quantification of drugs via CE which is related to poor LOD (limit of detection) of CE in determination of drugs particularly in biological samples. This is caused by the shorter cell path length (typically 50 to 100 μm) and lower volume of sample injected in comparison with HPLC.\textsuperscript{32} In order to overcome these limitations, some strategies such as off-line/online preconcentration and/or replacement the UV detector with more sensitive one have been emerged. Utilizing more sensitive detection systems (e.g. MS, laser induced fluorescence (LIF) and electrochemical detection (ED)) have their drawbacks. For example, as many compounds have not possesses naturally fluorescent chromophore, a time consuming sample derivatization step is normally needed for LIF detection. Although, if the alternative sensitive detector was replaced, sample pretreatment step is still necessary especially in complex biological media.

Most instruments cannot handle complex sample matrices directly and therefore a sample pre-treatment step is vital in an analytical procedure. Sample pre-treatment step is intensively required for extracting, isolating and concentrating the target analytes from complex matrices.\textsuperscript{33} Bringing the analytes to the detectable concentration levels is necessary before analysis. Sample preparation should be fast, compatible with analytical instrument, easy to use and with little solvent consumption.
Another option to improve the detector response is to increase the sample concentration prior to analysis. There are two practical strategies to pre-concentration, which are sample pre-concentration out of the capillary or performing on-line sample enhancing methods.

**Off-line pretreatment**
Sample preparation step including the extraction of interested analyte from the sample matrix which shows an important role in the case of biology related samples. Off-line pre-concentration methods are performed out of the analytical instrument and traditionally, there are two main techniques, liquid–liquid extraction (LLE) and solid-phase extraction (SPE). Although, these methods are efficient but they are complicated, time- and solvent-consuming and tedious.\textsuperscript{34,35} Loss of sample or even sample contamination have occurred in utilizing SPE cartridges and cause to make errors in quantitative analysis. Utilizing large amounts of extraction solvent in LLE, relatively alters the polarity of an aqueous sample solution so it increases possibility of solubilization of lipophilic analytes in the aqueous phase. Furthermore, the phase separation is difficult in LLE. Therefore, miniaturization of extraction performance seems to significant try to stop this possible waste amount of analyte.

In order to overcome such limitations, simple, inexpensive and microscale extraction methods were emerged in the mid-to-late 1990s. Solid phase microextraction (SPME) is a simple and efficient technique, which reduces the need of using large volume of solvents.\textsuperscript{36} Analytes adsorb on the fiber which is suitable to complex matrix such as plasma. SPME can be performed in two ways based on the position of the fiber relative to sample solution; direct immersion SPME (DI-SPME) that fiber was immersed within the aqueous sample and headspace (HS-SPME) which fiber was placed above the sample solution. Both DI- and HS-SPME techniques can be coupled with CE. In HS-SPME mode, fiber is not in direct contact with sample solution, therefore the fiber damage is diminished and generally more than 100 samples can be determined by the same device.\textsuperscript{37} Apart from the easy manual operation and applicability of SPME for complex biological matrix, SPME shows some disadvantages for examples the fiber is quiet expensive and fragile and recommended for single use only and irreproducible results occurred due to the ageing of fiber and/or clogging the pores of cartridge.

In order to diminish the use of organic solvents in LLE performance, miniaturization of LLE was emerged in 1996.\textsuperscript{38} Liquid-phase microextraction (LPME), as its name suggests, requires only several µL of solvent rather than several mL in conventional methods. The basic theory fall in the extraction of the aqueous analytes into small amount of organic phase. Thus, the equilibrium is attained in the short time than exhaustive LLE or SPE. As analytes collected into small volumes of acceptor phase, the enrichment factor is high. The more enrichment can be attained with evaporation the solvent and re-generation the analyte in the low amount of suitable carrier. In the case of complex matrix such as biological one, the enrichment factor is highly proportional to recovery of the target analyte or in another word it belongs to clean-up ability of the sample preparation methods.

LPME falls in three categories;
1. Single-drop microextraction (SDME)
2. Hollow-fiber microextraction (HF-LPME)
3. Dispersive liquid–liquid microextraction (DLLME)

In typical SDME, the tiny drop of organic solvent was hanging from the tip of a syringe and immersed into an aqueous sample solution in order to extraction the analytes from aqueous phase into hanging drop. HF-LPME developed by Pedersen-Bjergaard and Rasmussen in 1999\textsuperscript{39} after some difficulties associated with SDME such as low stability of the hanging drop and reproducibility. In this method, the acceptor solution was placed on a membrane hollow fiber by dipping the supported membrane into organic solvent, therefore the analytes extract into extracting solvent. The concept of supported liquid membrane (SLM) is the same but differs technically which the aqueous sample and acceptor phase were pumped into a SLM through the syringes creating flow system.\textsuperscript{39} As mentioned previously, the solvent consumption in LPME methods significantly decreased and in the SLM it is few volumes. SLM was used in limited number of paper maybe it is not affordable for most labs. Electromembrane extraction (EME), firstly was developed in 2006, is a combination of HF-LPME set-up and voltage-assisted extraction of analytes to an acceptor phase.\textsuperscript{40}

DLLME, a novel technique for pre-concentration, was developed in 2006 by Rezaee et al.\textsuperscript{41} This technique is attracting much attention because of its simplicity of operation, rapidity, low cost, high recovery, and good enrichment factor.\textsuperscript{42} Briefly, a dispersion was formed after rapid injecting of extracting and dispersing solvents mixture, then sedimentation was separated with a centrifuge and finally was collected for analysis.

**On-line enhancing methods**
To overcome the relatively poor detection limit associated with commercially poor UV detectors, several reports are available based on electrophoretic or chromatographic principles.

**Field Amplified Sample Stacking (FASS)**
The principle behind FASS, is shown in Figure 4. sample is prepared in solution of lower concentration than the BGE. Upon application a voltage, sample ions migrate towards BGE region and are concentrated. This accumulation or “stacking” increases sample concentration and results in an increased signal.\textsuperscript{43}
Hamidi and Jouyban

Figure 4. Schematic diagrams of a FASS model. (A) The sample is prepared in low conductivity media than BGE; (B) upon application of an electric field, sample is migrated through the capillary and stacked and (C) the concentrated analytes move toward the detector.

Large volume sample stacking (LVSS)

To improve the sensitivity, in contrary to normal injection, large amount of sample (dissolved in low-conductivity buffer) is loaded into capillary and is called LVSS. The large volume of sample matrix hinders the analyte stacking, therefore the sample matrix should be removed in order to enhancing the sensitivity (Figure 5). Accordingly, LVSS technique subdivided into two versions: matrix removal with or without polarity switching. In polarity switching mode, generally after stacking the analytes, the polarity is inverted to push out the matrix from the capillary. Then the polarity is changed to normal and stacked analyte migrated towards detection end by the aid of EOF. Inversion the polarity may be not affordable for all of the commercial CE instruments or in some cases polarity cannot be changed instantly and it cause to create irreproducible analysis.

Sweeping

Sweeping is characterized as a phenomenon which analytes was accumulated with the aid of pseudostationary phase (e.g. micelles, CDs, etc.). Sample solution conductivity should be as the same as the BGE, thus the conductivity along the capillary is homogenous. Despite of the stacking which concentration was happened when sample zone an BGE have different conductivity, in sweeping mode the sample conductivity is not matter but biological sample matrix effect should be regarded. The schematic view of sweeping is shown in Figure 6.

Isotachophoresis (ITP)

ITP is one of the well-known performed modes in CE. In contrary to other sample stacking versions, ITP is performed in the presence of two different conductivity buffers, leading and lagging electrolytes, which sample zone is surrounding by these buffers. After introducing the electrolytes and sample into capillary, voltage is applied (Figure 7). If the sample mobility is intermediate between electrolytes mobility, analytes is sandwiched between buffers and is focused. The principle of ITP can be applied to preconcentration in zone electrophoresis techniques (CZE, EKC), which is termed as transient ITP (tITP). In transient "pseudo-isotachophoresis" (p-ITP), better known as "acetonitrile stacking" (AS) acetonitrile acts as "pseudo terminating ions" and on the other hand salts act as "leading ions". This method have dual benefits; removing the proteins and compatible with high salt samples. Additionally, AS can be applicable for those CE-based sample preparation methods which analytes were extracted into viscose or low volatile...
solvent that needed to evaporate the solvent such as DLLME method.

**Figure 7.** Schematic diagrams of a ITP mode. (A) The sample is introduced between leading and terminating electrolytes; (B) due to a difference in electrical field, ions will move faster when come in the previous zone, and slower when come in the next zone. Therefore, they will return to their "own" zone and (C) the concentrated analytes move toward the detector.

**Partial filling technique (PFT)**

In PFT, the capillary is filled with BGE without chiral selector. Then, it is filled with a short plug of chiral selector and finally the procedure is followed by introducing the sample solution (Figure 8). After applying the voltage, the separated enantiomers move along the capillary towards the detector while they left chiral selector zone behind themselves. In addition to increase the sensitivity, PFT prevents the contamination of ionization source by chiral selector. The summery of different types of on-line preconcentration methods are listed in Table 2.

**Table 2.** On-line pre-concentration methods using CE.

| Method | Principle | Remarks |
|--------|-----------|---------|
| FASS   | In stacking modes analyte from a low-conductivity sample migrates towards a high-conductivity zone and is concentrated. In LVSS mode, removing the sample matrix occurred with/without polarity inversion. | Separation only cations or anions in one run. Not applicable for neutral analytes. Easy to perform by simply altering the electrical conductivities of the sample and BGE. |
| LVSS   | Unlike the stacking methods, sample solution conductivity is close to BGE, and upon applying the electric field into capillary analytes accumulate by pseudostationary phase. | Applicable for neutral and charged analytes. This method concentrates those analytes which interact with stationary phase migrate (sample purification aspect). Application is limited by availability of appropriate pseudostationary phase. |
| Sweeping | Analyte migrates between the highest (leading ion) and lowest (terminating ion) electrophoretic mobility zones. | Analysis of neutral compounds is not applicable. ITP technique is applicable to charged analytes and simultaneous analysis of oppositely charged analytes is not possible. On the other hand, this limitation can be understood as an advantage in terms of selective removal of neutral or oppositely charged (sample purification aspect). Applicable to samples with a significant matrix ion (acting as a leader). Applicable for low conductivity samples with the aid of leading ion. Direct analysis of water soluble supernatants of precipitated proteins samples. Precipitation agent (e.g., acetonitrile) serves simultaneously as terminating ion (transient pseudoisotachophoresis). |
| ITP    | Filling a discrete portion of the capillary with BGE containing chiral selector. | Low consumption of selector (vials do not contain selector). |

**Figure 8.** Schematic view of basic PFT performance by CE-MS. (A) Introduction of neutral chiral selector solution and the analyte, sequently; (B) separation of enantiomers in the chiral selector zone and (C) migration of single enantiomers towards the detector.
Cardiovascular diseases (CVDs)

According to American Heart Association annual report, more than 50% of mortality is related to CVDs.\(^4^9\) 25% of top 200 drugs advocates to cardiovascular drugs. On the other hand, CVDs are mostly associated with hypertension that approximately 1.56 billion people all over the world suffer from hypertension.\(^5^0\) Many of cardiovascular drugs and their metabolits possess single or multi chiral center/s which have stereoselective interaction with corresponding targets.\(^2\) It is reasonable that a chiral drug may show different therapeutic properties from its enantiomers or even racemic counterpart due to the different binding mode with biological targets.

Pharmacotherapy is the main management procedure of hypertension with one or more drugs from following classes: diuretics, β-blockers, α-agonists, calcium-channel blockers (CCB), angiotensin-converting enzyme (ACE)-inhibitors, anticoagulants, sympathomimetic drugs, antiarrhythmic drugs and angiotensin receptor blockers (ARBs).\(^3^1\) β-blocker drugs are one of the most important class of drugs in the pharmacotherapy management of hypertension. Recently the use of β-blocker drugs for the treatment of cardiac arrhythmias, cardioprotection after myocardial infarction (heart attack), and hypertension has been tremendously increased, therefore enantiomeric analysis is essential to understand their stereoselective biological properties. Although thiazides and diuretics are proposed as the first-line therapy for most patients with hypertension, β-blockers have a successful indication in patients with high-risk conditions such as heart failure, myocardial infarction (MI), coronary disease, and diabetes.\(^1^6\) Central inhibition of sympathetic nervous system outflow, inhibition of the renin–angiotensin system by reducing renin release from the juxtaglomerular apparatus, and sensitivity modification of baroreceptors are responsible for antihypertensive action of β-blockers.\(^1^7,1^9\) β-blockers also are used to treat other cardiovascular disorders such as angina, arrhythmias, bleeding esophageal varices, coronary artery disease, heart failure and migraines, and to prevent heart attacks.\(^5^2\)

Available β-blockers have one or more chiral centers. For those of β-blockers with one chiral center, the main biological effect is attributed to their (−) enantiomer. Enantioseparation of β-blockers because of therapeutic and forensics reasons has been gain much attentions. Nearly all β-blockers are used as their racemic form. β-blockers are classified according to their selectivity on β\(_1\) or β\(_2\) adrenergic receptors. The non selective β-blockers including: propranolol, oxprenolol, pindolol, nadolol, timolol and labetalol. Selective β\(_1\)-blockers including metoprolol, atenolol, esmolol, and acebutolol are recommended to whom β\(_2\)-blocker associated with adverse side effects for them. Such patients are suffer from asthma or diabetes, or patients with peripheral vascular disease or Raynaud’s disease.\(^5^3\) In addition to therapeutic purposes, most of cardiovascular drugs include in prohibited list according to the World Anti Doping Agency (WADA) regulation. Stereospecific pharmacokinetics of some beta blockers in humans after single oral doses of the racemates are summarized in Table 3.

### Table 3. Stereosepecific pharmacokinetics of some beta blockers in humans after single oral doses of the racemates.

| Drug     | Dose (mg) | Isomer | Cmax (ng/ml) | Tmax (h) | AUC (ng.h/mL) | CL\(_R\) (mL/min) | t\(_{1/2}\) | Protein binding (unbound ratio: +:−) | Ref. |
|----------|-----------|--------|--------------|----------|---------------|-----------------|---------|-------------------------------------|------|
| Acebutolol | 200       | -      | 221±106      | 2.4±1.5  | 1380±380      | 91±36           | 7.6±4   | 1.0                                 | 57   |
|           |           | +      | 209±91       |          | 1180±359      | 90±36           | 6.9±3.3 | In human plasma                     |      |
| Atenolol  | 50        | -      | 226±136      | 2.7±1.1  | 1640±602      | 129±32          | 6.13    | 6.08                                | 58   |
|           |           | +      | 251±138      |          | 1860±652      | 120±29          |         |                                     |      |
| Carvedilol| 25        | -      | 34.2±22.5    | 0.67     | 125±66        | 288±186         |         |                                     | 59   |
|           |           | +      | 73.5±44.3    |          |               |                 |         |                                     |      |
| Metoprolol| 200       | -      | 33±7         | 1.7±0.4  | 209±73        | 222±66          | 2.62    | 1.0                                 | 60   |
|           |           | +      | 36±10        | 1.6±0.5  | 244±90        | 170±55          | 2.85    | In human plasma                     | 61,62|
| Pindolol  | 15        | -      | 619±164      | 3.1±0.6  | 6760±1200     | 158±38          | 7.9±1.2 | 1.0                                 | 63,64|
|           |           | +      | 615±167      |          | 6950±850      | 150±25          | 8.2±0.7 | In human plasma                     |      |
| Sotalol   | 160       | -      | 81.7±31      |          | 329±118       | 4.5±1.2         | 0.86    | In human plasma                     | 65,66|
|           |           | +      | 46.5±25      |          | 217±114       | 5.2±2.4         |         |                                     |      |

Abbreviations: Cmax: maximum plasma concentration, Tmax: time to reach Cmax, AUC: area under the plasma concentration-time curve, CL\(_R\): renal clearance, t\(_{1/2}\): plasma half life.
Therefore, screening the low levels of enantiomers in biological fluids is important. Generally (S)-isomer of all \( \beta \)-blockers is more potent than R isomer in blocking \( \beta \)-adrenoceptors. (S)-Prpranolol is a drug that is 100 times more potent than its R form. Complementary study shows that d,l- and d-propranolol can inhibit the conversion of thyroxin to triiodothyronin. This lead to conclusion that single d-propranolol can be contribute to reduce plasma concentration of \( T_3 \) in hyperthyroidism patients.\textsuperscript{54,55}

The pharmacological potency of (S)-verapamil, a member of CCB class, is 20 times more than (R)-form. On the other hand, it was discovered later that verapamil exerts application in cancer chemotherapy at high doses following high cardiotoxicity. This problem can be overcome using R-enantiomer in cancer chemotherapy as following studies reveal.\textsuperscript{56} Table 4 provided the CE-based methods for quantification of chiral cardiovascular drugs.

| Analyte(s) | Chiral selector | Pre-treatment | Sample/Volume | Organic solvent(s)/volume | CE mode | Linear range For single enantiomer | Ref. |
|------------|----------------|---------------|---------------|---------------------------|---------|-----------------------------------|------|
| Pindolol, Oxprenolol, Propranolol | DM-\( \beta \)-CD + TM-\( \beta \)-CD | Filtration and dilution | Urine/- | - | CE/ FASI | 0.12-750 nM | 67 |
| Metoprolol, O-demethylmetoprolol, Metoprolol acidic metabolite, \( \alpha \)-hydroxymetoprolol | CM-\( \beta \)-CD | LLE | Urine/- | Ethyl acetate/ 5 mL | CE/UV | 1-50 \( \mu \)g/mL | 68 |
| Carteolol, Atenolol, Sotalol, Metoprolol, Esmolol, Propranolol | CM-\( \beta \)-CD | LLE | Human serum/ 250 \( \mu \)L | Ethanol/ 250 \( \mu \)L | CZE/UV/ FASI | 0.05-5 \( \mu \)g/mL, 0.25-25 \( \mu \)g/mL, 2.5-250 \( \mu \)g/mL | 69 |
| Labetalol | HDAS-\( \beta \)-CD + ODAS-\( \gamma \)-CD | SPE | Plasma/0.5 mL | \( \text{CH}_2\text{Cl}_2+ \) isopropanol + \( \text{NH}_4\text{OH} \)/ 300 \( \mu \)L | CE/UV | - | 70 |
| Warfarin | Methylated –\( \beta \)-CD | LLE | plasma/1 mL | \( \text{CH}_2\text{Cl}_2/5 \) mL | CE/UV | 0.2-0.4 mg/mL | 71 |
| Warfarin, Hydroxywarfarin | tapered capillary packed with 5- \( \mu \)m (3R,4S)-Whelk-O1 CSP | PP and SPE | plasma/- | - | CEC/ESI-MS | 0.1-5 \( \mu \)g/mL | 72 |
| Warfarin | Poly-L,L-SULV | SPE | Plasma/250 \( \mu \)L | - | MEKC/ ESI-MS/MS | 2-5000 ng/mL, 5-1000 ng/mL, 10-1000 ng/mL | 73 |
| Warfarin | DM-\( \beta \)-CD | Salting extraction | Urine/25 mL | ACN/25 mL | CE/UV /AS | 5-500 ng/mL | 74 |
| Arotinolol | Sodium taurocholate | SPE | Human serum/1 mL | - | MEKC/UV | 50-500 ng/mL | 75 |
| Clenbuterol | HE-\( \beta \)-CD | LLE | Human urine/ 2 mL | Hexane tert-butyl methyl ether/10 mL | CE/UV | 0.5-10 ng/mL | 76 |

---

Table 4. CE-based methods for quantification of chiral cardiovascular drugs in biological fluids.
Table 4 Continued.

| Compound          | Abbreviation | Extraction Method | Sample Volume | Eluent | Detection Method | Sensitivity  |
|------------------|--------------|-------------------|--------------|--------|-----------------|--------------|
| Clenbuterol      | DM-β-CD      | SPE               | Plasma/3 mL  | -      | CE/MS/PFT       | 50-500 µg/mL |
| Celiprolol       | S-β-CD       | LLE               | Human urine/ mL | 1     | CHCl<sub>2</sub> + propan-2-ol/5 mL | CE/UV | 0.06-0.14 mg/mL |
| Oxprenolol       | HP-β-CD      | LLE               | Urine/5 mL   | -      | Etyle acetate/8 mL | CE/UV | 0.4-16 µg/mL |
| Amlodipine       | HP-β-CD      | LLE               | Human serum/1 mL | -     | CHCl<sub>2</sub>/1 mL | CE/UV | 2-16 µg/mL |
| Amlodipine       | HP-α-CD      | SLM               | Human urine/ mL | 1.5   | -               | CE/UV | 10-500 ng/mL |
| Carvedilol       | HP-β-CD      | PP                | Serum        | -      | CE/UV           | 50-4000 ng/mL |
| Carvedilol       | Succinyl β-CD + methyl α-CD | LLE          | Plasma       | -      | Diethyl ether/1.1 mL | CE/LIF | 1.56-50 ng/mL |
| Carvedilol       | HP-β-CD      | PP and LLE        | Serum        | -      | Ethyl ether     | CE/UV | 1000-6200 ng/mL |
| Phenprocoumon    | α-CD         | Direct injection  | Urine        | -      | CE/LIF          | 0.2-20 µg/mL |
| Propranolol      | HP-β-CD      | HS-SPME           | Urine/5 mL   | -      | ACN/10 µL       | CE/UV/FASI| 0.05-10 µg/mL |
| Propranolol      | Poly (methylene glycol dimethacrylate) | In-tube SPME | Urine/1 mL   | 0.005 | MeOH/25 µL      | CEC/UV | 20-5000 µg/mL |
| Disopyramide     | S-β-CD       | PP and LLE        | Plasma/0.5 mL | CHCl<sub>2</sub>/800 µL | CD-EKC/ECL | 5×10<sup>-7</sup> to 2×10<sup>-5</sup> mol/L |
| Clenbuterol      | β-CD         | Centrifugation and Dilution | Urine     | -      | CE/UV/FASI-tTP  | 0.005-5 µg/mL |
| Metaproterenol, Methoxamine, Carvedilol | β-CD | PP | Serum/100 µL | -      | CE/UV/LVSS      | 0.5-3.5 µg/mL |
| Carvedilol       | CM-β-CD      | DLLME             | Plasma/0.5 mL | CHCl<sub>2</sub>/100 µL | CE/UV/FASI | 12.5-100 ng/mL |
| Verapamil        | CM-β-CD      | DLLME             | Plasma/400 µL | CHCl<sub>2</sub>/120 µL | CE/UV/FASI | 25-350 ng/mL |

Abbreviations: DM-β-CD: heptakis (2,6-di-O-methyl)-β-CD, TM-β-CD: heptakis (2,3,6-tri-O-methyl)-β-CD, CM-β-CD: carboxy methyl-β-cyclodextrin, HDAS-β-CD: heptakis (2,3,4,6-tetra-O-methyl)-β-cyclodextrin, ODAS-γ-CD: octakis(2,3,4,6-tetra-O-methyl)-γ-cyclodextrin, HP-β-CD: hydroxpropyl-β-cyclodextrin, HE-β-CD: Hydroxyethyl-β-cyclodextrin, β-CD: β-cyclodextrin, poly-L-L-SULV: polysodium N-undecenoyl-L-Leucyvalinate, S-β-CD: sulfated β-cyclodextrin, PP: protein precipitation, LLE: liquid-liquid extraction, DLLME: dispersive liquid-liquid microextraction, SPE: solid phase extraction, SPME: solid phase microextraction, HS-SPME: head space solid phase microextraction, SLM: supported liquid membrane, CH<sub>3</sub>Cl<sub>2</sub>: dichloromethane, NH<sub>4</sub>OH: ammonium hydroxide, CHCl<sub>2</sub>: chloroform, ACN: acetonitrile, MeOH: methanol, FASI: field amplified sample injection, CE: capillary electrophoresis, CEC: capillary electrophromatography, ESI-MS: electrospray ionization mass spectrometers, ECL: electrochemiluminescence, LIF: Laser-induced fluorescence, MEKC: micellar electrokinetic chromatography, PFT: partial filling technique, LVSS: large volume sample stacking, AS: acetonitrile stacking, tITP: transient isotachophoresis.
Conclusion

Chirality becomes the major concern in the modern pharmaceutical industry. This importance can be ascribed to a growing awareness that racemic drugs may have different pharmacokinetic and pharmacodynamic profiles owing to the fact that the biological systems is chiral selective. The FDA in 1992 approved a guideline based on investigation of enantiomers of drugs for their pharmacological and metabolic pathways, separately. A complete statement is available at www.fda.gov/cder/guidance/stereo.htm. Drugs with a chiral center consist of more than half of the currently used drugs. Understanding the contribution of individual enantiomers to follow the drugs action and concentration is necessary in drug development, pharmacokinetic and pharmacodynamic studies, TDM and forensic. Therefore, demands for accurate and precise analytical method for separation and determination of drugs enantiomers and their metabolites in biological fluids are highlighted. The sample pretreatment is vital to attain low matrix noise and enhancing sensitivity.

Cardiovascular drug therapy is important in the management of CVDs. Description of in vivo behavior of these drugs and their pharmacokinetics (absorption, distribution, metabolism and excretion) have been in circulation for recent decades. As before is mentioned, it is attributed to selectivity of biological environment to different enantiomers. Enantiomers are considered as different compounds, thus it is worthy to follow their pharmacological, pharmacokinetic, and toxicological activities distinctly.

Acknowledgments

This work is a part of a thesis by Samin Hamidi submitted for PhD degree (No. 93) and is supported by the Research Council, Tabriz University of Medical Sciences.

Conflict of interests

The author claims that there is no conflict of interest

References

1. Gohel MC. Overview on chirality and applications of stereo-selective dissolution testing in the formulation and development work. Dissolut Technol 2003;10:16-20. doi: 10.14227/DT100303P16
2. Khan A, Preskorn S, Wimalasena K. Single enantiomer drugs: Should they be developed? Essent Psychopharmacol 2006;7:15-23.
3. Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action: Molecular dissymmetry and physiological activity. Biochem J 1933;27:1257.
4. Stoker HS. General, organic, and biological chemistry; Brooks/Cole; 2012.
5. Rentsch KM. The importance of stereoselective determination of drugs in the clinical laboratory. J Biochem Biophys Methods 2002;54:1-9. doi:10.1016/S0165-022X(02)00124-0
6. Caslav ska J, Thomann W. Stereoselective determination of drugs and metabolites in body fluids, tissues and microsomal preparations by capillary electrophoresis (2000-2010). J Chromatogr A 2011;1218:588-601. doi:10.1016/j.chroma.2010.08.072
7. Kiran M, Yadav P, Deolekar P, Thakre V. Chiral chemistry in pharmacology—a review. Int J 2012;1:7-10.
8. Agranat I, Caner H, Caldwell J. Putting chirality to work: The strategy of chiral switches. Nat Rev Drug Discovery 2002;1:753-768. doi:10.1038/nrd915
9. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001;57:365-376. doi:10.1007/s002280100320
10. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004;363:1802-1811. doi:10.1016/S0140-6736(04)6308-3
11. Keurentjes J, Nabuurs L, Vegter E. Liquid membrane technology for the separation of racemic mixtures. J Membr Sci 1996;113:351-360. doi:10.1016/0376-7388(95)00176-X
12. Sirot EJ, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006;29:735-768. doi:10.2165/00002018-200629090-00001
13. Prichard B. Pharmacologic aspects of intrinsic sympathomimetic activity in beta-blocking drugs. Am J Cardiol 1987;59:F13-F7. doi:10.1016/0002-9149(87)90035-X
14. Cizmáriková R, Valentová J, Hutta J. Adrenergic beta-receptor blockers—a group of chiral drugs: Enantioseparation in the group of beta-blockers. Ceska Slov Farm 2004;53:9-17.
15. Wenda C, Rajendran A. Enantioseparation of flurbiprofen on amyllose-derived chiral stationary phase by supercritical fluid chromatography. J Chromatogr A 2009;1216:8750-8758. doi:10.1016/j.chroma.2009.02.047
16. Fanali S. Identification of chiral drug isomers by capillary electrophoresis. J Chromatogr A 1996;735:77-121. doi:10.1016/0021-9673(95)01327-X
17. Fanali S, Aturki Z, Desiderio C. New strategies for chiral analysis of drugs by capillary electrophoresis. Forensic Sci Int 1998;92:137-155. doi:10.1016/S0379-0738(98)00013-9
18. Meyring M, Chankvetadze B, Blaschke G. Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrophoresis. J Chromatogr A
20. Chankvetadze B, Yamamoto C, Okamoto Y. Enantioseparation of selected chiral sulfoxides using polysaccharide-type chiral stationary phases and polar organic, polar aqueous–organic and normal-phase eluents. *J Chromatogr A* 2001;922:127-137. doi:10.1016/S0021-9673(01)00958-X

21. Gübitz G, Schmid MG. Chiral separation by capillary electromigration techniques. *J Chromatogr A* 2008;1204:140-156. doi:10.1016/j.chroma.2008.07.071

22. Wongwan S, Scriba G. Development and validation of a capillary electrophoresis assay for the determination of the stereoisomeric purity of chloroquine enantiomers. *Electrophoresis* 2011;32:2669-2672. doi: 10.1002/elps.201000610

23. Fanali S. Enantioselective determination by capillary electrophoresis with cyclodextrins as chiral selectors. *Chirality* 2000;875:89-122. doi:10.1016/S0021-9673(99)01309-6

24. Chankvetadze B, Blaschke G. Enantioseparations in capillary electromigration: Recent developments and future trends. *J Chromatogr A* 2001;906:309-363. doi:10.1016/S0021-9673(00)01124-9

25. Preinerstorfer B, Lammerhofer M, Lindner W. Advances in enantioselective separations using electromigration capillary techniques. *Electrophoresis* 2009;30:100-132. doi:10.1002/elps.200800607

26. Gübitz G, Schmid MG. Recent progress in chiral separation principles in capillary electrophoresis. *Electrophoresis* 2000;21:4112-4135. doi:10.1002/1522-2683(200012)21:18<4112::AID-ELPS4112>3.0.CO;2-T

27. Gübitz G, Schmid MG. Advances in chiral separation using capillary electromigration techniques. *Electrophoresis* 2007;28:114-126. doi:10.1002/elps.200600411

28. Huo Y, Kok WT. Recent applications in ccc. *Electrophoresis* 2008;29:80-93. doi:10.1002/elps.200700639

29. Chankvetadze B, Lindner W, Scriba G. Enantioomer separations in capillary electrophoresis in the case of equal binding constants of the enantiomers with a chiral selector: Commentary on the feasibility of the concept. *Anal Chem* 2004;76:4256-4260. doi: 10.1021/ac0355202

30. Dodziuk H, Koźmiński W, Ejchart A. Nmr studies of chiral recognition by cyclodextrins. *Chirality* 2004;16:90-105. doi: 10.1002/chir.10304

31. Wren SA, Rowe RC. Theoretical aspects of chiral separation in capillary electrophoresis: I. Initial evaluation of a model. *J Chromatogr A* 1992;603:235-241. doi:10.1016/0021-9673(92)85366-2

32. Hempel G. Strategies to improve the sensitivity in capillary electrophoresis for the analysis of drugs in biological fluids. *Electrophoresis* 2000;21:691-698. doi: 10.1002/(SICI)1522-2683(20000301)21:4<691::AID-ELPS691>3.0.CO;2-U

33. Morita I, Sawada J-i. Capillary electrophoresis with on-line sample pretreatment for the analysis of biological samples with direct injection. *J Chromatogr A* 1993;641:375-381. doi:10.1016/0021-9673(93)80154-Z

34. Namera A, Saito T. Recent advances in unique sample preparation techniques for bioanalysis. *Bioanalysis* 2013;5:915-932. doi:10.4155/bio.13.52

35. Ashri NY, Abdel-Rehim M. Sample treatment based on extraction techniques in biological matrices. *Bioanalysis* 2011;3:2003-2018. doi:10.4155/bio.11.201

36. Arthur CL, Pawliszyn J. Solid phase microextraction with thermal desorption using fused silica optical fibers. *Anal Chem* 1990;62:2145-2148. doi:10.1021/ac00128a019

37. Kataoka H, Saito K. Recent advances in sime techniques in biomedical analysis. *J Pharm Biomed Anal* 2011;54:926-950. doi:10.1016/j.jpba.2010.12.010

38. Liu H, Dasgupta PK. Anal. Chem. in a drop. Solvent extraction in a microdrop. *Anal Chem* 1996;68:1817-1821. doi: 10.1021/ac960145h

39. Pedersen-Bjergaard S, Rasmussen KE. Liquid-liquid microextraction with thermal desorption using fused silica optical fibers. *Electrophoresis* 2011;32:2669-2672. doi: 10.1002/elps.201000610

40. Pedersen-Bjergaard S, Rasmussen KE. Electrokinetik migration across artificial liquid membranes: New concept for rapid sample preparation of biological fluids prior to capillary electrophoresis. *Anal Chem* 1999;71:2650-2656. doi:10.1021/ac990055n

41. Rezaee M, Assadi Y, Hosseini M-RM, Aghaei E, Ahmadi F, Berijani S. Determination of organic compounds in water using dispersive liquid–liquid microextraction. *J Chromatogr A* 2006;1109:183-190. doi:10.1016/j.chroma.2006.01.025

42. Herrera-Herrera AV, Asensio-Ramos M, Hernández-Borges J, Rodríguez-Delgado MA. Dispersive liquid-liquid microextraction for determination of organic analytes. *TrAC Trends Anal Chem* 2010;29:728-751. doi:10.1016/j.trac.2010.03.016

43. Bharadwaj R, Santiago JG. Dynamics of field-amplified sample stacking. *J Fluid Mech* 2005;543:57-92. doi:10.1017/S0022112005005975

44. Kawai T, Koino H, Sueyoshi K, Kitagawa F,
Otsuka K. Highly sensitive chiral analysis in capillary electrophoresis with large-volume sample stacking with an electroosmotic flow pump. J Chromatogr A 2012;1246:28-34. doi:10.1016/j.chroma.2012.02.001

45. Quirino JP, Kim J-B, Terabe S. Sweeping: Concentration mechanism and applications to high-sensitivity analysis in capillary electrophoresis. J Chromatogr A 2002;965:357-373. doi:10.1016/S0021-9673(01)01499-6

46. Liu HY, Hwang TJ, Tsai IL, Kuo CH. Use of high-conductivity sample solution with sweeping-micellar electrokinetic capillary chromatography for trace-level quantification of paliperidone in human plasma. Electrophoresis 2015;36:534-542. doi: 10.1002/elps.201400230

47. Beckers JL, Boček P. Sample stacking in capillary zone electrophoresis: Principles, advantages and limitations. Electrophoresis 2000;21:2747-2767. doi: 10.1002/1522-2683(20000801)21:14<2747::AID-ELPS2747-3.0.CO;2-Z

48. Amini A, Paulsen-Sörman U, Westerlund D. Principle and applications of the partial filling technique in capillary electrophoresis. Chromatographia 1999;50:497-506. doi:10.1007/BF02490748

49. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2012 update a report from the american heart association. Circulation 2012;125:e2-e220. doi:10.1161/CIR.0b013e31823ac046

50. Dhakam Z, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351-356. doi: 10.1097/HJH.0b013e282f83c9

51. Trialists’Collaboration BPLT. Effects of ace inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 2000;355:955-964. doi:10.1016/S0140-6736(00)03307-9

52. Dean L. Pubmed clinical q&a [internet]. Bethesda (MD): National Center for Biotechnology Information/NCBI (US)[http://www.ncbi.nlm.nih.gov/books/NBK62349] 2008.

53. Mehvar R, Brooks DR. Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans. J Pharm Pharm Sci 2001;4:185-200.

54. Stoschitzky K, Lindner W, Zernig G. Racemic beta-blockers-fixed combinations of different drugs. J Clin Basic Cardiol 1998;1:15-19.

55. Harrower A, Fyffe J, Horn D, Strong J. Thyroxine and triiodothyronine levels in hyperthyroid patients during treatment with propranolol. Clin Endocrinol 1977;7:41-4. doi: 10.1111/j.1365-2265.1977.tb02938.x

56. Tolcher AW, Cowan KH, Solomon D, Ognibene F, Goldspiel B, Chang R, et al. Phase i crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J Clin Oncol 1996;14:1173-1184.

57. Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F. Pharmacokinetics of acebutolol enantiomers in humans. J Pharm Sci 1991;80:313-316. doi: 10.1002/jps.2600800405

58. Mehvar R, Gross ME, Kreamer RN. Pharmacokinetics of atenolol enantiomers in humans and rats. J Pharm Sci 1990;79:881-885. doi:10.1002/jps.2600791007

59. Gehr T, Tenero D, Boyle D, Qian Y, Sica D, Shusterman N. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269-277. doi:10.1007/s002280050628

60. Lennard M, Tucker G, Silas J, Freestone S, Ramsay L, Woods H. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clin Pharmacol Ther 1983;34:732-737.

61. Somogyi AA, Bochner F, Sallustio BC. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 1992;51:379-387. doi: 10.1038/clpt.1992.37

62. Hsyu P-H, Giacomini KM. Stereoselective renal clearance of pindolol in humans. J Clin Invest 1985;76:1720. doi: 10.1172/JCI112161

63. Carr RA, Foster RT, Lewanczuk RZ, Hamilton PG. Pharmacokinetics of sotalol enantiomers in humans. J Clin Pharmacol 1992;32:1105-1109. doi: 10.1177/009127009203201208

64. Carr RA, Pasutto FM, Lewanczuk RZ, Foster RT. Protein binding of sotalol enantiomers in young and elderly human and rat serum using ultrafiltration. Biopharm Drug Dispos 1995;16:705-712. doi:10.1002/bdd.2510160809

65. Lindner W, Rath M, Stoschitzky K, Semmelrock H. Pharmacokinetic data of propranolol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269-277. doi:10.1007/s002280050628

66. Walle U, Walle T, Bai S, Olanoff L. Stereoselective inhibition of pindolol renal clearance by cimetidine in humans. Clin Pharmacol Ther 1992;51:379-387. doi: 10.1038/clpt.1992.37

67. Jin Y, Chen C, Meng L, Chen J, Li M, Zhu Z. Simultaneous and sensitive capillary electrophoretic enantioseparation of three β-blockers with the combination of achiral ionic liquid and dual cd derivatives. Talanta 2012;89:149-154. doi:10.1016/j.talanta.2011.12.005

68. Lim H-K, Linh PT, Hong C-H, Kim K-H, Kang S. Enantioselective determination of metoprolol and major metabolites in human urine by capillary
electrophoresis. J Chromatogr B Biomed Sci Appl 2001;755:259-264. doi:10.1016/S0378-4347(01)00118-9

69. Huang L, Lin JM, Yu L, Xu L, Chen G. Field-amplified on-line sample stacking for simultaneous enantioseparation and determination of some β-blockers using capillary electrophoresis. Electrophoresis 2008;29:3588-3594. doi: 10.1002/elps.200700811

70. Goel TV, Nikelly JG, Simpson RC, Matuszewski BK. Chiral separation of labetalol stereoisomers in human plasma by capillary electrophoresis. J Chromatogr A 2004;1027:213-221. doi:10.1016/j.chroma.2003.08.082

71. Gareil P, Gramond J, Guyon F. Separation and determination of warfarin enantiomers in human plasma samples by capillary zone electrophoresis using a methylated β-cyclodextrin-containing electrolyte. J Chromatogr B Biomed Sci Appl 1993;615:317-325. doi:10.1016/0378-4347(93)80347-7

72. Zheng J, Shamsi SA. Combination of chiral capillary electrochromatography with electrospray ionization mass spectrometry: Method development and assay of warfarin enantiomers in human plasma. Anal Chem 2003;75:6295-6305. doi:10.1021/ac030193j

73. Wang X, Hou J, Jann M, Hon YY, Shamsi SA. Development of a chiral micellar electrokinetic chromatography–tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: Application to the analysis of patients serum samples. J Chromatogr A 2013;1271:207-216. doi:10.1016/j.chroma.2012.11.046

74. Wang M, Cai Z, Xu L. Coupling of acetonitrile deproteinization and salt-extraction out with acetonitrile stacking in chiral capillary electrophoresis for the determination of warfarin enantiomers. J Chromatogr A 2011;1218:4045-4051. doi:10.1016/j.chroma.2011.04.067

75. Hefnawy MM. Micellar electrokinetic capillary chromatography determination of (+) s and (-) r ar tinol in serum using UV detection and solid phase extraction. Chirality 2002;14:67-71. doi:10.1002/chir.888

76. Gausepohl C, Blaschke G. Stereoselective determination of clenbuterol in human urine by capillary electrophoresis. J Chromatogr B Biomed Sci Appl 1998;713:443-446. doi:10.1016/S0378-4347(98)00178-9

77. Toussaint B, Palmer M, Chiap P, Hubert P, Crommen J. On-line coupling of partial filling-capillary zone electrophoresis with mass spectrometry for the separation of clenbuterol enantiomers. Electrophoresis 2001;22:1363-1372. doi: 10.1002/1522-2683(200105)22:7<1363::AID-ELEPS1363>3.0.CO;2-Q

78. Daali Y, Cherkauoi S, Christen P, Veuthey J-L. Experimental design for enantioselective separation of celiprolol by capillary electrophoresis using sulfated β-cyclodextrin. Electrophoresis 1999;20:3424-3431. doi: 10.1002/(SICI)1522-2683(19991010)20:17<3424::AID-ELEPS3424>3.0.CO;2-Z

79. Li F, Cooper SF, Mikkelsen SR. Enantioselective determination of oxprenolol and its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis. J Chromatogr B Biomed Appl 1995;674:277-285. doi:10.1016/0378-4347(95)00307-X

80. Wang R, Jia Z-p, Fan J-J, Chen L-R, Xie H, Ma J, et al. Ce, with hydroxypropyl-β-cyclodextrin as chiral selector, for separation and determination of the enantiomers of amldipine in the serum of hypertension patients. Chromatographia 2007;65:575-579. doi:10.1365/s10337-007-0212-z

81. Owens PK, Fell AF, Coleman MW, Berridge JC. Effect of charged and uncharged chiral additives on the resolution of amldipine enantiomers in liquid chromatography and capillary electrophoresis. J Chromatogr A 1998;797:187-195. doi:10.1016/S0021-9797(97)00995-3

82. Clohs L, McElrane KM. Development of a capillary electrophoresis assay for the determination of carvedilol enantiomers in serum using cyclodextrins. J Pharm Biomed Anal 2001;24:545-554. doi:10.1016/S0731-7085(00)00468-4

83. Behn F, Michels S, Läer S, Blaschke G. Separation of carvedilol enantiomers in very small volumes of human plasma by capillary electrophoresis with laser-induced fluorescence. J Chromatogr B Biomed Sci Appl 2001;755:111-117. doi:10.1016/S0378-4347(01)00045-7

84. Clohs L, McElrane KM. Comparison between capillary electrophoresis and high-performance liquid chromatography for the stereoselective analysis of carvedilol in serum. J Pharm Biomed Anal 2003;31:407-412. doi:10.1016/S0731-7085(02)00609-X

85. Burjanadze N, Blaschke G. Enantioseparation of the anticoagulant drug phenprocoumon in capillary electrophoresis with UV and laser-induced fluorescence detection and application of the method to urine samples. Electrophoresis 2001;22:3281-3285. doi: 10.1002/1522-2683(200109)22:15<3281::AID-ELEPS3281>3.0.CO;2-C

86. Zhou X, Li X, Zeng Z. Solid-phase microextraction coupled with capillary electrophoresis for the determination of propranolol enantiomers in urine using a sol–gel derived calix [4] arene fiber. J Chromatogr A 2006;1104:359-365. doi:10.1016/j.chroma.2005.11.126

87. Lin B, Zheng MM, Ng SC, Feng YQ. Development of in-tube solid-phase microextraction coupled to pressure-assisted cec and its application to the analysis of propranolol enantiomers in human urine.
Pre-concentration in bioanalysis of chiral cardiovascular drugs

88. Fang L, Kang J, Yin Xb, Yang X, Wang E. Coupling with end-column electrochemiluminescence detection for chiral separation of disopyramide. *Electrophoresis* 2007;28:2771-2780. doi: 10.1002/elps.200700174

89. Huang L, Lin Q, Chen Y, Chen G. Transient isotachophoresis with field-amplified sample injection for on-line preconcentration and enantioseparation of some β-agonists. *Anal Methods* 2011;3:294-248. doi: 10.1039/C0AY00556H

90. Denola NL, Quiming NS, Saito Y, Jinno K. Simultaneous enantioseparation and sensitivity enhancement of basic drugs using large-volume sample stacking. *Electrophoresis* 2007;28:3542-3552. doi: 10.1002/elps.200700299

91. Hamidi S, Soltani S, Jouyban A. A dispersive liquid-liquid microextraction and chiral separation of carvedilol in human plasma using capillary electrophoresis. *Bioanalysis* 2015;7:1107-1117. doi:10.4155/bio.15.51

92. Hamidi S, Jouyban A. Capillary electrophoresis with uv detection, on-line stacking and off-line dispersive liquid–liquid microextraction for determination of verapamil enantiomers in plasma. *Anal Methods* 2015;7:5820-5829. doi: 10.1039/C5AY00916B